Our
Team

Our world-class, multidisciplinary team of psychedelic, drug development, commercialisation and digital experts are united by their determination to help people living with neuropsychiatric disorders.

Our
Executive
Team
Our
Board
of
Directors
Our
Scientific
Advisors
Our
Investors

Dr. Robin L Carhart-Harris

Professor Matthew W Johnson PhD

Other investors include investment entities (e.g. funds and family offices) and individuals.